PL 9654
Alternative Names: PL-9654; PL9654McrLatest Information Update: 17 Jul 2023
At a glance
- Originator Palatin Technologies
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Choroidal neovascularisation; Diabetic retinopathy; Retinal disorders
Most Recent Events
- 14 Jul 2023 Preclinical trials in Retinal disorders in USA (SC) (Palatin Technologies pipeline, July 2023)
- 14 Jul 2023 Preclinical trials in Retinal disorders in USA (Topical)
- 14 Jul 2023 Palatin Technologies announces intention to submit IND application in 2023 (Palatin Technologies pipeline, July 2023)